Novo says study shows Levemir reduces body weight

Denmark’s Novo Nordisk, the world’s biggest maker of insulin, said on Tuesday a new study showed its long-acting insulin Levemir reduces body weight and improves blood glucose levels in Type 2 Diabetes patients.

The new data, a subanalysis of 2,377 patients from a larger multinational study, indicated that individuals taking Levemir lost 0.7 kilograms after 14 weeks, compared to a baseline.

"The weight loss was more pronounced in those who entered the trial at higher weight,” Novo said in a statement.

The data was presented on Tuesday at the world congress of the International Diabetes Federation in Capetown, South Africa.

Print Version
Tell-a-Friend

RELATED ARTICLES:

Gastric bypass cuts heart risks   Parents foster significant misperceptions of children’s weight   Steroids Not as Effective in Obese Asthma Patients   Genes affect weight loss drug effectiveness   Intestine liner helps weight loss, U.S. firm says   Diabetes linked to poor weight loss with surgery   Insurers recoup obesity surgery cost in 2-4 years   How gastric bypass rapidly reverses diabetes symptoms   Adults who eat eggs for breakfast lose 65 percent more weight   Internet, alcohol and sleep tied to girls’ weight   Day care babies gain more weight: study   Laparoscopic gastric bypass provides better results